Form 4: Contineum Therapeutics Director Evert B. Schimmelpennink Granted Stock Options

Director Evert B. Schimmelpennink received stock options for 29,500 shares of Contineum Therapeutics, Inc. (CTNM) on May 24, 2024, as part of the company's Non-Employee Director Compensation Program.

Summary

• On May 24, 2024, Evert B. Schimmelpennink, a director of Contineum Therapeutics, Inc. (CTNM), was granted stock options to purchase 29,500 shares of Class A Common Stock.
• The options were granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended.
• The exercise price of the options is $15.76 per share.
• One-third of the option shares vest on April 5, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry, to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice in the biotech industry.
• The vesting schedule of one-third after one year and the remainder over the subsequent 24 months is a typical vesting arrangement.
• Comparing the size of the grant to similar companies would require further analysis of Contineum Therapeutics' compensation policies and market capitalization.

Stakeholder Impact

• Shareholders: The option grant aligns the director's interests with increasing shareholder value.
• Employees: The grant is part of a broader compensation program, potentially impacting employee morale and retention.

Key Dates